PT2222669E - Derivados de oxadiazole ativos em esfingosina-1-fosfato (s1p) - Google Patents
Derivados de oxadiazole ativos em esfingosina-1-fosfato (s1p)Info
- Publication number
- PT2222669E PT2222669E PT88640214T PT08864021T PT2222669E PT 2222669 E PT2222669 E PT 2222669E PT 88640214 T PT88640214 T PT 88640214T PT 08864021 T PT08864021 T PT 08864021T PT 2222669 E PT2222669 E PT 2222669E
- Authority
- PT
- Portugal
- Prior art keywords
- sphingosine
- sip
- oxadiazole derivatives
- phosphate
- derivatives active
- Prior art date
Links
- 150000004866 oxadiazoles Chemical class 0.000 title abstract 2
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 title 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0725120A GB0725120D0 (en) | 2007-12-21 | 2007-12-21 | Compounds |
| GB0821918A GB0821918D0 (en) | 2008-12-01 | 2008-12-01 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2222669E true PT2222669E (pt) | 2013-10-28 |
Family
ID=40342566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT88640214T PT2222669E (pt) | 2007-12-21 | 2008-12-19 | Derivados de oxadiazole ativos em esfingosina-1-fosfato (s1p) |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US8222245B2 (pt) |
| EP (1) | EP2222669B1 (pt) |
| JP (1) | JP2011506569A (pt) |
| KR (1) | KR20100108566A (pt) |
| CN (1) | CN101945863B (pt) |
| AR (1) | AR069916A1 (pt) |
| AU (1) | AU2008339988B2 (pt) |
| BR (1) | BRPI0820131A2 (pt) |
| CA (1) | CA2710130A1 (pt) |
| CO (1) | CO6290646A2 (pt) |
| CR (1) | CR11579A (pt) |
| DK (1) | DK2222669T3 (pt) |
| DO (1) | DOP2010000194A (pt) |
| EA (1) | EA017691B1 (pt) |
| ES (1) | ES2434730T3 (pt) |
| HK (1) | HK1142062A1 (pt) |
| HR (1) | HRP20130957T1 (pt) |
| IL (1) | IL206235A0 (pt) |
| MA (1) | MA31924B1 (pt) |
| NZ (1) | NZ585996A (pt) |
| PE (1) | PE20091339A1 (pt) |
| PL (1) | PL2222669T3 (pt) |
| PT (1) | PT2222669E (pt) |
| RS (1) | RS53038B (pt) |
| SI (1) | SI2222669T1 (pt) |
| TW (1) | TWI415847B (pt) |
| UY (1) | UY31570A1 (pt) |
| WO (1) | WO2009080725A1 (pt) |
| ZA (1) | ZA201003963B (pt) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007026341A1 (de) | 2007-06-06 | 2008-12-11 | Merck Patent Gmbh | Benzoxazolonderivate |
| DE102007032507A1 (de) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| PE20091057A1 (es) | 2007-12-19 | 2009-07-20 | Lilly Co Eli | Antagonistas del receptor mineralcorticoide y metodos de uso |
| GB0725102D0 (en) * | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| GB0725105D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| DE102007061963A1 (de) | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | Pyridazinonderivate |
| GB0725101D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| DE102008019907A1 (de) | 2008-04-21 | 2009-10-22 | Merck Patent Gmbh | Pyridazinonderivate |
| GB0807910D0 (en) | 2008-04-30 | 2008-06-04 | Glaxo Group Ltd | Compounds |
| DE102008028905A1 (de) | 2008-06-18 | 2009-12-24 | Merck Patent Gmbh | 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate |
| ES2434247T3 (es) | 2008-12-22 | 2013-12-16 | Merck Patent Gmbh | Formas polimórficas novedosas de dihidrogenofosfato de 6-(1-metil-1H-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-bencil}-2H-piridazin-3-ona y procesos de fabricación de las mismas |
| GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
| WO2011028927A1 (en) * | 2009-09-04 | 2011-03-10 | Allergan, Inc. | Selective sphingosine-1-phosphate receptor antagonists |
| CN103649056B (zh) | 2011-05-10 | 2016-04-27 | 吉利德科学公司 | 作为离子通道调节剂的稠合杂环化合物 |
| CN102250035A (zh) * | 2011-06-10 | 2011-11-23 | 北京富卡生物技术有限公司 | 二芳基取代-1，3，4-噁二唑化合物的合成方法和其药物用途 |
| TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| NO3175985T3 (pt) | 2011-07-01 | 2018-04-28 | ||
| RU2543485C2 (ru) * | 2013-02-26 | 2015-03-10 | Андрей Александрович Иващенко | Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения |
| CN104844535A (zh) * | 2014-02-13 | 2015-08-19 | 吉利德科学公司 | 用于制备稠合杂环离子通道调节剂的方法 |
| MA40082B1 (fr) | 2014-08-20 | 2019-09-30 | Bristol Myers Squibb Co | Nouveau compose de substitution sphingosine phosphate utile traitement maladie rhumatisme |
| EP3227263B1 (en) * | 2014-12-01 | 2019-04-10 | Idorsia Pharmaceuticals Ltd | Cxcr7 receptor modulators |
| WO2022173795A1 (en) * | 2021-02-10 | 2022-08-18 | Icahn School Of Medicine At Mount Sinai | OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS |
| WO2023081328A1 (en) * | 2021-11-04 | 2023-05-11 | Valo Health, Inc. | Histone deacetylase 6 inhibitor compounds and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3964478B2 (ja) | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬 |
| JPH1180026A (ja) | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| US7429579B2 (en) | 2000-11-14 | 2008-09-30 | Smithkline Beecham, Plc | Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents) |
| CA2488117A1 (en) | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
| AU2004249664A1 (en) | 2003-05-19 | 2004-12-29 | Irm Llc | Immunosuppressant compounds and compositions |
| AU2004277947A1 (en) * | 2003-10-01 | 2005-04-14 | Merck & Co., Inc. | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists |
| WO2005058848A1 (en) | 2003-12-17 | 2005-06-30 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
| US8039674B2 (en) * | 2004-06-23 | 2011-10-18 | Ono Pharmaceutical Co., Ltd. | Compound having S1P receptor binding potency and use thereof |
| GB0414795D0 (en) | 2004-07-01 | 2004-08-04 | Glaxo Group Ltd | Compounds |
| JP2008517915A (ja) | 2004-10-22 | 2008-05-29 | メルク エンド カムパニー インコーポレーテッド | Ｓ１ｐ受容体アゴニストとしての２−（アリール）アザシクリルメチルカルボキシレート、スルホネート、ホスホネート、ホスフィネート及びヘテロ環 |
| JP4318087B2 (ja) | 2004-12-13 | 2009-08-19 | 小野薬品工業株式会社 | アミノカルボン酸誘導体およびその医薬用途 |
| ES2365747T3 (es) * | 2005-03-23 | 2011-10-10 | Actelion Pharmaceuticals Ltd. | Derivados de benzo[c]tiofeno hidrogenados como inmunomoduladores. |
| US7605269B2 (en) | 2005-03-23 | 2009-10-20 | Actelion Pharmaceuticals Ltd. | Thiophene derivatives as Sphingosine-1-phosphate-1 receptor agonists |
| KR20070121013A (ko) * | 2005-04-22 | 2007-12-26 | 다이이찌 산쿄 가부시키가이샤 | 헤테로 고리 화합물 |
| WO2006131336A1 (en) * | 2005-06-08 | 2006-12-14 | Novartis Ag | POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS |
| CA2619101A1 (en) | 2005-08-23 | 2007-03-01 | Irm Llc | Immunosuppressant compounds and compositions |
| TW200738694A (en) | 2005-11-24 | 2007-10-16 | Glaxo Group Ltd | Chemical compounds |
| CA2648303C (en) * | 2006-04-03 | 2014-07-15 | Astellas Pharma Inc. | 5-[monocyclic(hetero)arylsubstituted-1,2,4-oxadliazol-3-yl]-(fused heteroaryl substituted) compounds and their use as s1p1 agonists |
| EP2097371A2 (en) * | 2006-11-21 | 2009-09-09 | University Of Virginia Patent Foundation | Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
| GB0725101D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| GB0725104D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| GB0725102D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| GB0725105D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
-
2008
- 2008-12-18 PE PE2008002122A patent/PE20091339A1/es not_active Application Discontinuation
- 2008-12-19 EP EP08864021.4A patent/EP2222669B1/en active Active
- 2008-12-19 TW TW097149553A patent/TWI415847B/zh not_active IP Right Cessation
- 2008-12-19 RS RS20130479A patent/RS53038B/en unknown
- 2008-12-19 AU AU2008339988A patent/AU2008339988B2/en not_active Expired - Fee Related
- 2008-12-19 BR BRPI0820131 patent/BRPI0820131A2/pt not_active IP Right Cessation
- 2008-12-19 JP JP2010538741A patent/JP2011506569A/ja active Pending
- 2008-12-19 KR KR1020107016167A patent/KR20100108566A/ko not_active Application Discontinuation
- 2008-12-19 WO PCT/EP2008/067965 patent/WO2009080725A1/en active Application Filing
- 2008-12-19 PL PL08864021T patent/PL2222669T3/pl unknown
- 2008-12-19 DK DK08864021.4T patent/DK2222669T3/da active
- 2008-12-19 UY UY31570A patent/UY31570A1/es unknown
- 2008-12-19 AR ARP080105590A patent/AR069916A1/es not_active Application Discontinuation
- 2008-12-19 ES ES08864021T patent/ES2434730T3/es active Active
- 2008-12-19 NZ NZ585996A patent/NZ585996A/en not_active IP Right Cessation
- 2008-12-19 CN CN2008801273456A patent/CN101945863B/zh not_active Expired - Fee Related
- 2008-12-19 EA EA201070782A patent/EA017691B1/ru not_active IP Right Cessation
- 2008-12-19 SI SI200831050T patent/SI2222669T1/sl unknown
- 2008-12-19 US US12/747,205 patent/US8222245B2/en not_active Expired - Fee Related
- 2008-12-19 CA CA2710130A patent/CA2710130A1/en not_active Abandoned
- 2008-12-19 PT PT88640214T patent/PT2222669E/pt unknown
-
2009
- 2009-01-28 US US12/360,886 patent/US20100174065A1/en not_active Abandoned
-
2010
- 2010-06-03 ZA ZA2010/03963A patent/ZA201003963B/en unknown
- 2010-06-07 IL IL206235A patent/IL206235A0/en unknown
- 2010-06-16 MA MA32926A patent/MA31924B1/fr unknown
- 2010-06-21 CO CO10074455A patent/CO6290646A2/es active IP Right Grant
- 2010-06-21 DO DO2010000194A patent/DOP2010000194A/es unknown
- 2010-07-21 CR CR11579A patent/CR11579A/es not_active Application Discontinuation
- 2010-09-03 HK HK10108378.3A patent/HK1142062A1/xx not_active IP Right Cessation
-
2013
- 2013-10-09 HR HRP20130957AT patent/HRP20130957T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2222669E (pt) | Derivados de oxadiazole ativos em esfingosina-1-fosfato (s1p) | |
| GB0625648D0 (en) | Compounds | |
| MY156822A (en) | Indole derivatives as s1p1 receptor agonists | |
| IN2012DN01233A (pt) | ||
| MY146969A (en) | Dpp iv inhibitor formulations | |
| JO2686B1 (en) | Vehicles | |
| MX2009004716A (es) | Compuestos y composiciones en la forma de inhibidores de quinasa de proteina. | |
| TW200722081A (en) | New therapeutic combinations for the treatment or prevention of depression | |
| MX2013013692A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de beta secretasa 1 (bace1) y/o beta secretasa 2 (bace2). | |
| MX2009008253A (es) | Derivados de 2-aminopiridina utiles como inhibidores de cinasa. | |
| MX2010003117A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. | |
| NO20092476L (no) | Antibakterielle polycykliske ureaforbindelser | |
| MX2007008924A (es) | Compuestos quimicos. | |
| MX2009009491A (es) | Compuestos y composiciones como moduladores de la actividad del gpr119. | |
| MX2013007558A (es) | 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2). | |
| TW200806300A (en) | New therapeutic combinations for the treatment of depression | |
| MX2009009153A (es) | Pirano-pirazol-aminas. | |
| MX2009006345A (es) | Compuestos utiles como inhibidores de proteina cinasa. | |
| MX2010002210A (es) | Derivados de catecolamina y profarmacos de los mismos. | |
| TW200942524A (en) | Novel aminomethyl benzene derivatives | |
| MX2009009154A (es) | Derivados de espiro-pirano-pirazol. | |
| MX2013014194A (es) | 1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2). | |
| MY150931A (en) | Substituted oxazolidinones and their use | |
| EP2746254A3 (en) | Oxadiazole derivative active on sphingosine-1-phosphate (s1p) | |
| WO2008148573A3 (de) | Arzeimittel mit einer wirkstoffkombination enthaltend pantothensäure oder deren derivate zur behandlung von allergischen symptomen |